An interventional study of Pulsed-Field Ablation with FARAWAVE Catheter System in Persistent Atrial Fibrillation, Atrial Fibrillation (AF) and Atrial Remodeling, sponsored by Taipei Veterans General Hospital, Taiwan. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Atrial Fibrillation with a site in Taiwan — 17 open to participants now, 25 under way, 3 of them phase 3. Atrial Fibrillation · Taiwan.
Among the 95 studies in Atrial Fibrillation with a site in Taiwan, this one is the 60th largest by planned enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2026, is one of 34 with no phase, reaches primary completion later than 17 of the 24 other live ones, and was the 93rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →17 of the 95 studies in Atrial Fibrillation with a site in Taiwan are open now. Recruiting first, the newest first:
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 18–80
Boston Scientific Corporation · Sites in Taiwan, Croatia, Czechia and 1 more country
Ages 18+
Ting-Yung Chang · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Defense Medical Center, Taiwan · Sites in Taiwan
Ages 40 days–85 days
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 24 · Phase 4 4
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 448 across the 67 interventional studies, 343 across the 25 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 95 have an industry lead sponsor. The 10 most frequent:
Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.
Taipei Veterans General Hospital, Taiwan has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies in Atrial Fibrillation with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111443Phase 3Chang Gung Memorial HospitalEffect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation | 2026-11-30 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06632925Taipei Veterans General Hospital, TaiwanUtility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study | 2027-01-01 |
| NCT06735534Boston Scientific CorporationRepeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | 2027-04 |
| NCT06960252Ting-Yung ChangCycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Atrial Fibrillation with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.
This is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE / FARADRIVE Catheter and FARASTAR System.
The primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.
Background and Rationale Atrial fibrillation (AF) is associated with progressive electrical and structural remodeling of the left atrium. Electrical remodeling typically reverses within a week after restoration of sinus rhythm, whereas structural remodeling takes longer - generally 2 to 4 months - and successful ablation has been shown to improve left atrial transport function. Pre-procedural assessment with echocardiographic left atrial strain and delayed-enhancement MRI may help predict the extent of reverse remodeling after ablation.
Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses pulsed electric fields to create focal lesions selectively targeting cardiomyocytes, while largely sparing surrounding structures such as the esophagus, phrenic nerve, and blood vessels. Compared with radiofrequency ablation (RFA), PFA can create larger and deeper lesions with fewer applications, with a potentially reduced risk of collateral injury. Beyond pulmonary vein isolation (PVI), PFA has also been applied to other atrial substrates, including the posterior wall and mitral line.
A recent study suggested that mean pulmonary arterial pressure did not worsen in patients with pre-existing pulmonary hypertension undergoing repeat PFA for recurrent AF. However, the impact of PFA on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unknown. This study aims to characterize changes in atrial function and structural remodeling 3 to 12 months after PFA for PVI and extensive substrate modification, and to explore its relationship with procedural outcomes.
Study Design This is a prospective, single-center, single-arm observational clinical investigation conducted at Taipei Veterans General Hospital. Thirty patients with persistent AF will undergo the index ablation procedure using the FARAWAVE Catheter, FARADRIVE Catheter, and FARASTAR System (Boston Scientific). Enrollment will cease once approximately 30 subjects have been accrued. An interim endpoint analysis will be performed once all subjects have completed their 6-month follow-up. All participants will be followed for up to 12 months.
Procedure Pre-procedural care will follow the standard institutional protocol for AF ablation cases, with AF classification (paroxysmal vs. non-paroxysmal) defined according to the 2024 HRS consensus on catheter ablation of AF. Pre-procedural evaluation includes transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), cardiac CT and MRI, and 14-day Holter monitoring.
The ablation procedure is performed under deep sedation or general anesthesia, with PFA targeting pulmonary vein isolation and posterior wall isolation. Additional substrate modification may be performed using PFA at the physician's discretion. Conventional invasive hemodynamic assessment of left atrial function - including mean pulmonary artery pressure (mPAP), pulmonary arterial wedge pressure, cardiac output, vascular resistance, and right atrial pressure - will be performed before and after PFA during the procedure.
Post-procedural assessments include 12-lead ECG and in-hospital Holter monitoring within 3 days following PFA. At 3 to 12 months after the procedure, participants will undergo repeat echocardiography, cardiac CT and MRI, ECG, and 14-day Holter monitoring. Invasive hemodynamic assessment will be repeated approximately 3 months after the procedure.
Endpoints The primary endpoint is left atrial structural remodeling, including changes in LA size, atrial strain, extent of atrial fibrosis, and other atrial hemodynamic functions. The secondary endpoint is AF-free survival within 3 to 12 months following PFA. The main scientific question is to elucidate atrial remodeling following non-thermal ablation with PFA and its relationship to ablation outcomes.
Safety Monitoring All adverse events (AEs) and serious adverse events (SAEs) will be captured and classified by the investigator according to relatedness (procedure-related, device-related, cardiovascular-related, arrhythmia-related, heart failure-related), seriousness, timing (pre-procedure, during ablation, post-ablation), and diagnosis. Pre-specified serious adverse events of interest include cardiac tamponade or perforation, death, esophageal perforating complications, gastric motility / pyloric spasm disorders, heart block, myocardial infarction, hospitalization due to cardiovascular or pulmonary PFA system- or procedure-related events, pericarditis, peripheral or organ thromboembolism, pulmonary vein stenosis, severe hemolysis with subsequent renal failure or significant anemia, stroke, transient ischemic attack, unresolved phrenic nerve palsy or paresis, and vascular access complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with persistent atrial fibrillation undergoing the index ablation procedure with pulsed-field ablation (PFA) for pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. The procedure is performed under deep sedation or general anesthesia using the FARAWAVE Catheter, FARADRIVE Catheter, and FARASTAR System. Invasive hemodynamic assessment (mean pulmonary artery pressure, pulmonary arterial wedge pressure, cardiac output, vascular resistance, right atrial pressure) is performed immediately before and after PFA during the procedure, and repeated approximately 3 months post-procedure. All subjects are followed for 12 months, with structural and functional reassessment by echocardiography, cardiac CT, cardiac MRI, and 14-day Holter monitoring at 3 to 12 months.
Device: Pulsed-Field Ablation with FARAWAVE Catheter System
Pulsed-field ablation is performed using the FARAWAVE / FARADRIVE Catheter and FARASTAR System (Boston Scientific) under deep sedation or general anesthesia. PFA is delivered to achieve pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. Invasive hemodynamic assessment is performed pre- and post-PFA during the index procedure and repeated at approximately 3 months.
Also known as: FARAWAVE Catheter, FARADRIVE Catheter, FARASTAR System, FARAPULSE PFA System
Change in Left Atrial Anteroposterior Diameter
Change from baseline in left atrial anteroposterior (AP) diameter measured by transthoracic echocardiography.
Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure
Change in Left Atrial Volume Index
Change from baseline in left atrial volume index measured by transthoracic echocardiography.
Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure
Change in Left Atrial Reservoir Strain
Change from baseline in left atrial reservoir strain assessed by transthoracic echocardiography with speckle-tracking analysis.
Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure
Change in Left Atrial Conduit Strain
Change from baseline in left atrial conduit strain assessed by transthoracic echocardiography with speckle-tracking analysis.
Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure
Change in Left Atrial Contractile Strain
Change from baseline in left atrial contractile strain assessed by transthoracic echocardiography with speckle-tracking analysis.
Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure
Change in Extent of Left Atrial Fibrosis
Change from baseline in the extent of left atrial fibrosis assessed by delayed-enhancement cardiac magnetic resonance imaging (MRI), expressed as the percentage of fibrotic left atrial wall relative to total left atrial wall area.
Time frame: Baseline and 3 to 12 months post-procedure
Change in Mean Pulmonary Artery Pressure (mPAP)
Change from baseline in mean pulmonary artery pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.
Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure
Change in Pulmonary Arterial Wedge Pressure (PAWP)
Change from baseline in pulmonary arterial wedge pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.
Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure
Change in Cardiac Output
Change from baseline in cardiac output. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.
Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure
Change in Pulmonary Vascular Resistance
Change from baseline in pulmonary vascular resistance. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.
Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure
Change in Right Atrial Pressure
Change from baseline in right atrial pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.
Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure
Atrial Fibrillation-Free Survival
Proportion of subjects free from any documented atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting ≥30 seconds following a 90-day blanking period after the index pulsed-field ablation procedure. Recurrence is assessed by 12-lead ECG and 14-day Holter monitoring performed between 3 and 12 months post-procedure.
Time frame: 3 to 12 months post-procedure
Correlation Between Atrial Remodeling and Ablation Outcome
Correlation between post-procedural atrial structural remodeling parameters (left atrial size, atrial strain, extent of atrial fibrosis on delayed-enhancement cardiac MRI, and invasively measured atrial hemodynamic function) and atrial fibrillation-free survival following pulsed-field ablation. Each parameter's association with recurrence is expressed as a correlation coefficient. This analysis aims to identify imaging- and hemodynamic-based predictors of ablation success and to characterize the relationship between reverse atrial remodeling and clinical outcome.
Time frame: 3 to 12 months post-procedure
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. All study data analysis will be conducted within Taipei Veterans General Hospital, and no external data transfers are planned. Participant data will be anonymized and stored on a secure institutional server accessible only to authorized study personnel.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 29 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Veterans General Hospital, Taiwan →